1.Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, et al: Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015, 131:e29–322.
2.Frazier OH, Myers TJ: Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 1999, 68:734–741.
3.Grady KL, Meyer PM, Mattea A, Dressler D, Ormaza S, White-Williams C, Chillcott S, Kaan A, Loo A, Todd B, et al: Change in quality of life from before to after discharge following left ventricular assist device implantation. J Heart Lung Transplant 2003, 22:322–333.
4.Dhar K, Moulton AM, Rome E, Qiu F, Kittrell J, Raichlin E, Zolty R, Um JY, Moulton MJ, Basma H, et al: Targeted myocardial gene expression in failing hearts by RNA sequencing. J Transl Med 2016, 14:327.
5.Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR: Serial gene expression profiling in the intact human heart. J Heart Lung Transplant 2006, 25:579–588.
6.Weitzel LB, Ambardekar AV, Brieke A, Cleveland JC, Serkova NJ, Wischmeyer PE, Lowes BD: Left ventricular assist device effects on metabolic substrates in the failing heart. PLoS One 2013, 8:e60292.
7.Mondal NK, Sorensen E, Hiivala N, Feller E, Griffith B, Wu ZJ: Oxidative stress, DNA damage and repair in heart failure patients after implantation of continuous flow left ventricular assist devices. Int J Med Sci 2013, 10:883–893.
8.Tsutsui H, Kinugawa S, Matsushima S: Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011, 301:H2181–2190.
9.Lowes BD, Rome E, Dhar K, Kittrell J, Eudy JD, John Y, Moulton AM, J Z, Redder R, Anderson D, Raichlin E: Damaging Cardiac and Cancer Genetic Variants in the LVAD Population. The VAD Journal 2015, 1.
10.Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, et al: Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 2002, 8:750–760.
11.Ambardekar AV, Walker JS, Walker LA, Cleveland JC, Jr., Lowes BD, Buttrick PM: Incomplete recovery of myocyte contractile function despite improvement of myocardial architecture with left ventricular assist device support. Circ Heart Fail 2011, 4:425–432.
12.Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, et al: Therapeutic Molecular Phenotype of beta-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet 2015, 8:270–283.
13.Lowes BD, Baker ML, Blaxall BC: Gene expression profile of the recovering human heart. Eur Heart J 2007, 28:522–524.
14.Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, et al: Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002, 346:1357–1365.
15.Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, et al: Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997, 100:2315–2324.
16.Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR: Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight 2017, 2:e89169.
17.McCarthy DJ, Chen Y, Smyth GK: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 2012, 40:4288–4297.
18.Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139–140.
19.Ahmad IM, Temme JB, Abdalla MY, Zimmerman MC: Redox status in workers occupationally exposed to long-term low levels of ionizing radiation: A pilot study. Redox Rep 2016, 21:139–145.
20.Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko YS, Matsushita T: Gap junction alterations in human cardiac disease. Cardiovasc Res 2004, 62:368–377.
21.Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, et al: The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant 2019, 38:114–126.
22.Patel N, Gluck JA, Radojevic J, Coleman CI, Baker WL: Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis. ESC Heart Fail 2018, 5:1141–1149.
23.Diakos NA, Navankasattusas S, Abel ED, Rutter J, McCreath L, Ferrin P, McKellar SH, Miller DV, Park SY, Richardson RS, et al: Evidence of Glycolysis Up-Regulation and Pyruvate Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning. JACC Basic Transl Sci 2016, 1:432–444.
24.Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER: The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond) 2014, 11:10.
25.Bolfer L, Estrada AH, Winter B, Taggart K, Lourenço F, Terada N, Byrne BJ, Conlon TJ, Pacak CA: The Role of the Pyruvate Dehydrogenase Kinase 4 (PDK4) Gene Mutation in the Development of Dilated Cardiomyopathy in Dobermanpinschers and Potential Application of Cardiac Gene Therapy. Molecular Therapy 2016, 24:S70-S71.
26.Taggart K, Estrada A, Thompson P, Lourenco F, Kirmani S, Suzuki-Hatano S, Pacak CA: PDK4 Deficiency Induces Intrinsic Apoptosis in Response to Starvation in Fibroblasts from Doberman Pinschers with Dilated Cardiomyopathy. Biores Open Access 2017, 6:182–191.
27.Zhao G, Jeoung NH, Burgess SC, Rosaaen-Stowe KA, Inagaki T, Latif S, Shelton JM, McAnally J, Bassel-Duby R, Harris RA, et al: Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2008, 294:H936–943.
28.Jeong JY, Jeoung NH, Park KG, Lee IK: Transcriptional regulation of pyruvate dehydrogenase kinase. Diabetes Metab J 2012, 36:328–335.
29.Leibetseder V, Humpeler S, Svoboda M, Schmid D, Thalhammer T, Zuckermann A, Marktl W, Ekmekcioglu C: Clock genes display rhythmic expression in human hearts. Chronobiol Int 2009, 26:621–636.
30.Stow LR, Richards J, Cheng KY, Lynch IJ, Jeffers LA, Greenlee MM, Cain BD, Wingo CS, Gumz ML: The circadian protein period 1 contributes to blood pressure control and coordinately regulates renal sodium transport genes. Hypertension 2012, 59:1151–1156.
31.Young ME: The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function. Am J Physiol Heart Circ Physiol 2006, 290:H1–16.
32.Rains JL, Jain SK: Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011, 50:567–575.
33.Cheng Y, Zhang C: MicroRNA–21 in cardiovascular disease. J Cardiovasc Transl Res 2010, 3:251–255.
34.Caruso R, Verde A, Campolo J, Milazzo F, Russo C, Boroni C, Parolini M, Trunfio S, Paino R, Martinelli L, et al: Severity of oxidative stress and inflammatory activation in end-stage heart failure patients are unaltered after 1 month of left ventricular mechanical assistance. Cytokine 2012, 59:138–144.
35.Lundgren s, Lyden E, Stoller D, Hyden M, Burdorf A, Zolty R, Um J, Lowes B: Electrocardiographic characteristics, antiarrhythmic utilization, and outcomes in patients with left ventricular assist devices. The VAD Journal 2018, 4.
36.Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ: Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003, 41:1096–1106.
37.Birks EJ, Hall JL, Barton PJ, Grindle S, Latif N, Hardy JP, Rider JE, Banner NR, Khaghani A, Miller LW, Yacoub MH: Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005, 112:I57–64.
38.Razeghi P, Mukhopadhyay M, Myers TJ, Williams JN, Moravec CS, Frazier OH, Taegtmeyer H: Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. Ann Thorac Surg 2001, 72:2044–2050.
39.Uray IP, Connelly JH, Thomazy V, Shipley GL, Vaughn WK, Frazier OH, Taegtmeyer H, Davies PJ: Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 2002, 21:771–782.
40.Chen Y, Park S, Li Y, Missov E, Hou M, Han X, Hall JL, Miller LW, Bache RJ: Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 2003, 14:251–260.
41.Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJ, Frazier OH, Taegtmeyer H: Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 2002, 97:203–209.
42.Mitchell A, Guan W, Staggs R, Hamel A, Hozayen S, Adhikari N, Grindle S, Desir S, John R, Hall JL, Eckman P: Identification of differentially expressed transcripts and pathways in blood one week and six months following implant of left ventricular assist devices. PLoS One 2013, 8:e77951.
43.de Weger RA, Schipper ME, Siera-de Koning E, van der Weide P, van Oosterhout MF, Quadir R, Steenbergen-Nakken H, Lahpor JR, de Jonge N, Bovenschen N: Proteomic profiling of the human failing heart after left ventricular assist device support. J Heart Lung Transplant 2011, 30:497–506.
44.Mohamedali B, Bhat G: The Influence of Pre-Left Ventricular Assist Device (LVAD) Implantation Glomerular Filtration Rate on Long-Term LVAD Outcomes. Heart Lung Circ 2017, 26:1216–1223.
45.Mehra MR, Uriel N, Naka Y, Cleveland JC, Jr., Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, et al: A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med 2019, 380:1618–1627.